10x Genomics Stock Investor Sentiment

TXG Stock  USD 14.15  0.80  5.35%   
Roughly 56% of 10X Genomics' investor base is looking to short. The analysis of overall sentiment of trading 10X Genomics stock suggests that many investors are alarmed at this time. The current market sentiment, together with 10X Genomics' historical and current headlines, can help investors time the market. In addition, many technical investors use 10X Genomics stock news signals to limit their universe of possible portfolio assets.

Panic Vs Confidence

44

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use 10X Genomics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward 10X Genomics.

10X Historical Sentiment

Although 10X Genomics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding 10X, such as negative comments on social media and news outlets, may cause fear in the market and push 10X Genomics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of 10X.
  

10X Genomics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards 10X Genomics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

10X Genomics Historical Investor Sentiment

Investor biases related to 10X Genomics' public news can be used to forecast risks associated with an investment in 10X. The trend in average sentiment can be used to explain how an investor holding 10X can time the market purely based on public headlines and social activities around 10X Genomics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
10X Genomics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for 10X Genomics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average 10X Genomics news discussions. The higher the estimate score, the more favorable the investor's outlook on 10X Genomics.
over six months ago at news.google.com         
Serge Saxonov Sells 2000 Shares of 10x Genomics, Inc. Stock - MarketBeat
Google News at Macroaxis
over six months ago at thelincolnianonline.com         
10x Genomics Research Coverage Started at Wolfe Research
news
over six months ago at thelincolnianonline.com         
10x Genomics Coverage Initiated by Analysts at Guggenheim
news
over six months ago at thelincolnianonline.com         
10x Genomics Rating Increased to Neutral at Bank of America
news
over six months ago at thelincolnianonline.com         
10x Genomics Stock Rating Upgraded by Bank of America
news
over a year ago at finance.yahoo.com         
High Sensitivity and Specificity of the Xenium Platform from 10x Genomics Outperforms NanoStrings Co...
Yahoo News
over a year ago at hawaiinewsnow.com         
High Sensitivity and Specificity of the Xenium Platform from 10x Genomics Outperforms NanoStrings Co...
news
over a year ago at seekingalpha.com         
BofA raises 10x Genomics to buy, cites fading headwinds
seekingalpha News
over a year ago at hawaiinewsnow.com         
10x Genomics and NIH CARD to Create Comprehensive Single Cell Atlas of the Human Brain
news
over a year ago at seekingalpha.com         
10x Genomics files patent case against Curio
seekingalpha News
over a year ago at reuters.com         
10x Genomics sues rival Curio over gene-sequencing technology
reuters
over a year ago at thelincolnianonline.com         
Geode Capital Management LLC Has 80.12 Million Stake in 10x Genomics, Inc.
news
over a year ago at thelincolnianonline.com         
Brokerages Set 10x Genomics, Inc. Price Target at 60.78
news
over a year ago at thelincolnianonline.com         
10x Genomics, Inc. Shares Purchased by JPMorgan Chase Co.
news
over a year ago at thelincolnianonline.com         
Insider Selling 10x Genomics, Inc. Insider Sells 150,129.76 in Stock
news
Far too much social signal, news, headlines, and media speculation about 10X Genomics that are available to investors today. That information is available publicly through 10X media outlets and privately through word of mouth or via 10X internal channels. However, regardless of the origin, that massive amount of 10X data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of 10X Genomics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of 10X Genomics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to 10X Genomics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive 10X Genomics alpha.

10X Genomics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
10x Genomics short call reiterated at Hedgeye, sees potential for 50 percent downside - Seeking Alpha
09/26/2024
2
10x Genomics Upgraded to Strong Buy Heres Why
10/23/2024
3
UBS Group Issues Pessimistic Forecast for 10x Genomics Stock Price
11/01/2024
4
10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference
11/07/2024
5
Disposition of 534 shares by Serge Saxonov of 10X Genomics at 55.064 subject to Rule 16b-3
11/12/2024
6
Sumitomo Mitsui Trust Group Inc. Has 143.91 Million Holdings in 10x Genomics, Inc.
11/13/2024
7
Baillie Gifford Co. Reduces Stock Holdings in 10x Genomics, Inc.
11/14/2024
8
10x Genomics, Inc. Among the Best Genomics Stocks to Buy Right Now - Yahoo Finance
11/19/2024
9
Disposition of 1850 shares by Serge Saxonov of 10X Genomics subject to Rule 16b-3
11/21/2024
10
Disposition of 5807 shares by Benjamin Hindson of 10X Genomics at 13.6878 subject to Rule 16b-3
11/22/2024
11
10x genomics chief scientific officer sells 79,485 in stock
11/25/2024
12
Point72 Asset Management L.P. Makes New 27.78 Million Investment in 10x Genomics, Inc.
12/06/2024
13
XTX Topco Ltd Purchases 31,844 Shares of 10x Genomics, Inc. - MarketBeat
12/11/2024

Complementary Tools for 10X Stock analysis

When running 10X Genomics' price analysis, check to measure 10X Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 10X Genomics is operating at the current time. Most of 10X Genomics' value examination focuses on studying past and present price action to predict the probability of 10X Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 10X Genomics' price. Additionally, you may evaluate how the addition of 10X Genomics to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes